[1]马昕,周紫如,孙梦菲,等.SLC44A5蛋白在食管鳞状细胞癌组织中的表达及其临床意义[J].陕西医学杂志,2026,(8):1123-1130,1137.[doi:DOI:10.3969/j.issn.1000-7377.2026.08.019]
　MA Xin,ZHOU Ziru,SUN Mengfei,et al.Expression of SLC44A5 protein in esophageal squamous cell carcinoma tissues and its clinical significance[J].,2026,(8):1123-1130,1137.[doi:DOI:10.3969/j.issn.1000-7377.2026.08.019]
点击复制

SLC44A5蛋白在食管鳞状细胞癌组织中的表达及其临床意义

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
期数:
2026年8期
页码:
1123-1130,1137
栏目:
临床病理
出版日期:
2026-08-05

文章信息/Info

Title:
Expression of SLC44A5 protein in esophageal squamous cell carcinoma tissues and its clinical significance
作者:
马昕1; 2; 周紫如2; 孙梦菲2; 李艺冬2; 王天鸿2; 黄萌2; 程艺2; 崔晓宾1; 2
（1.南京医科大学鼓楼临床医学院，江苏 南京 210008；2.南京大学医学院附属鼓楼医院病理科，江苏 南京 210008）
Author(s):
MA Xin1; 2; ZHOU Ziru2; SUN Mengfei2; LI Yidong2; WANG Tianhong2; HUANG Meng2; CHENG Yi2; CUI Xiaobin1; 2
（1.Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University,Nanjing 210008,China;2.Department of Pathology,Affiliated Drum Tower Hospital,Medical School of Nanjing University,Nanjing 210008,China）
关键词:
食管鳞状细胞癌; 溶质载体家族44成员5; 临床病理特征; 预后; 细胞增殖; 细胞迁移
Keywords:
Esophageal squamous cell carcinoma; Solute carrier family 44 member 5; Clinicopathological characteristics; Prognosis; Cell proliferation; Cell migration
分类号:
R 735.1
DOI:
DOI:10.3969/j.issn.1000-7377.2026.08.019
文献标志码:
A
摘要:
目的：探讨溶质载体家族44成员5（SLC44A5）蛋白在食管鳞状细胞癌（ESCC）组织中的表达，评估其与患者临床病理特征及预后的关系，并初步分析其对ESCC细胞恶性生物学行为的影响。方法：选取ESCC患者221例，共收集患者术后石蜡包埋组织样本398例，其中ESCC组织221例，癌旁正常组织177例。采用免疫组织化学染色法检测ESCC组织和癌旁正常组织中SLC44A5蛋白表达水平，分析其与患者临床病理特征的关系。通过受试者工作特征（ROC）曲线分析SLC44A5蛋白表达对ESCC的诊断价值。随访并统计ESCC患者总生存期（OS），依据免疫组织化学评分将患者分为SLC44A5低表达组（37例）和SLC44A5高表达组（70例）。绘制Kaplan-Meier生存曲线，并采用Log-rank检验分析SLC44A5蛋白表达与ESCC患者预后的关系。用Cox比例风险回归模型分析ESCC患者预后的影响因素。选取食管鳞癌细胞系TE-1、Eca-109细胞，随机分为si-Control组和si-SLC44A5组。采用Western blot检测SLC44A5蛋白表达水平以评价敲低效率。采用CCK-8法、克隆形成实验和Transwell实验检测SLC44A5蛋白对TE-1、Eca-109细胞增殖及迁移的影响。结果：SLC44A5蛋白主要在ESCC细胞胞浆中高表达。ESCC组织中SLC44A5蛋白表达高于癌旁正常组织（P<0.05）。SLC44A5高表达与患者年龄≥60岁、有淋巴结转移和TNM分期Ⅲ期有关（均P<0.05）。SLC44A5蛋白诊断ESCC的曲线下面积（AUC）为0.885（P<0.05）。与SLC44A5低表达组比较，SLC44A5高表达组患者生存率更低（P<0.05）。SLC44A5高表达是ESCC患者预后的独立危险因素（P<0.05）。不同浓度SLC44A5 siRNA均可不同程度降低SLC44A5蛋白表达。综合敲低效率及细胞状态，最终选择75 nmol/L作为后续功能实验浓度。从第3天开始，si-SLC44A5组TE-1、Eca-109细胞吸光度值低于si-Control组，且第4天两组吸光度值比较差异有统计学意义（均P<0.05）。si-SLC44A5组TE-1、Eca-109细胞克隆形成数及迁移数低于si-Control组（均P<0.05）。结论：SLC44A5在ESCC组织中高表达，与患者临床病理特征及预后有关。体外实验表明，敲低SLC44A5能够抑制ESCC细胞增殖和迁移。
Abstract:
Objective:To investigate the expression of solute carrier family 44 member 5 (SLC44A5) protein in esophageal squamous cell carcinoma (ESCC) tissues,evaluate its correlations with clinicopathological characteristics and prognosis of patients,and preliminarily explore its effects on the malignant biological behaviors of ESCC cells.Methods:A total of 221 patients with ESCC were enrolled.A total of 398 postoperative paraffin-embedded tissue samples were collected,including 221 ESCC tissues and 177 adjacent normal tissues.Immunohistochemical staining was performed to detect the expression level of SLC44A5 protein in ESCC tissues and adjacent normal tissues,and the relationships between SLC44A5 expression and clinicopathological characteristics were analyzed.The ROC curve was used to assess the diagnostic value of SLC44A5 protein for ESCC.The overall survival (OS) of ESCC patients was followed up and recorded.According to the immunohistochemical scores,the patients were divided into low SLC44A5 expression group (37 cases) and high SLC44A5 expression group (70 cases).The Kaplan-Meier survival curve was plotted,and the Log-rank test was adopted to analyze the correlation between SLC44A5 protein expression and the prognosis of ESCC patients.The Cox proportional hazards regression model was used to analyze the prognostic influencing factors of ESCC patients.ESCC cell lines TE-1 and Eca-109 were selected and randomly divided into si-Control group and si-SLC44A5 group.Western blot was used to detect the expression level of SLC44A5 protein to evaluate the knockdown efficiency.CCK-8 assay,colony formation assay and Transwell assay were applied to detect the effects of SLC44A5 protein on the proliferation and migration of TE-1 and Eca-109 cells.Results:SLC44A5 protein was mainly highly expressed in the cytoplasm of ESCC cells.The expression level of SLC44A5 protein in ESCC tissues was significantly higher than that in adjacent normal tissues (P<0.05).High expression of SLC44A5 was correlated with age≥60 years,lymph node metastasis and TNM stage Ⅲ (all P<0.05).The AUC of SLC44A5 protein for diagnosing ESCC was 0.885 (P<0.05).Patients in the high SLC44A5 expression group had a lower survival rate compared with those in the low expression group (P<0.05).High expression of SLC44A5 was an independent risk factor for poor prognosis in ESCC patients (P<0.05).SLC44A5 siRNA at different concentrations could reduce the expression of SLC44A5 protein to varying degrees.Considering the knockdown efficiency and cell status comprehensively,75 nmol/L was finally selected as the concentration for subsequent functional experiments.Starting from the 3rd day,the absorbance values of TE-1 and Eca-109 cells in the si-SLC44A5 group were lower than those in the si-Control group,and the differences were statistically significant on the 4th day (all P<0.05).The number of colonies and migrated cells of TE-1 and Eca-109 in the si-SLC44A5 group was significantly lower than that in the si-Control group (all P<0.05).Conclusion:SLC44A5 is highly expressed in ESCC tissues,which is correlated with the clinicopathological characteristics and prognosis of patients.In vitro experiments demonstrate that knockdown of SLC44A5 can inhibit the proliferation and migration of ESCC cells.

参考文献/References:

[1]BRAY F,LAVERSANNE M,SUNG H,et al.Global cancer statistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2024,74(3):229-263.
[2]QI L,SUN M,LIU W,et al.Global esophageal cancer epidemiology in 2022 and predictions for 2050:A comprehensive analysis and projections based on GLOBOCAN data[J].Chin Med J (Engl),2024,137(24):3108-3116.
[3]DISIENA M,PERELMAN A,BIRK J,et al.Esophageal Cancer:An updated review[J].South Med J,2021,114(3):161-168.
[4]SADDOUGHI S A,REINERSMAN J M,ZHUKOV Y O,et al.Survival after surgical resection of stage Ⅳ esophageal cancer[J].Ann Thorac Surg,2017,103(1):261-266.
[5]INAZU M.Choline transporter-like proteins CTLs/SLC44 family as a novel molecular target for cancer therapy[J].Biopharm Drug Dispos,2014,35(8):431-449.
[6]YAO N,LI W,XU G,et al.Choline metabolism and its implications in cancer[J].Front Oncol,2023,13:1234887.
[7]GLUNDE K,BHUJWALLA Z M,RONEN S M.Choline metabolism in malignant transformation[J].Nat Rev Cancer,2011,11(12):835-848.
[8]HEDTKE V,BAKOVIC M.Choline transport for phospholipid synthesis:An emerging role of choline transporter-like protein 1[J].Exp Biol Med (Maywood),2019,244(8):655-662.
[9]GLUNDE K,PENET M F,JIANG L,et al.Choline metabolism-based molecular diagnosis of cancer:An update[J].Expert Rev Mol Diagn,2015,15(6):735-747.
[10]GLUNDE K,SERKOVA N J.Therapeutic targets and biomarkers identified in cancer choline phospholipid metabolism[J].Pharmacogenomics,2006,7(7):1109-1123.
[11]MICHEL V,YUAN Z,RAMSUBIR S,et al.Choline transport for phospholipid synthesis[J].Exp Biol Med (Maywood),2006,231(5):490-504.
[12]REDEKER K M,BROCKMOLLER J.Diversity of human choline transporters:Substrate specificity,kinetic properties,and inhibitor sensitivity[J].Biochem Pharmacol,2025,242(Pt 2):117343.
[13]LIU M C,YU B,XIA Y,et al.Choline transporters are required for oligodendrocyte differentiation and myelin sheath formation in mouse postnatal brain[J].Cell Rep,2025,44(7):115852.
[14]CRACIUNESCU C N,ALBRIGHT C D,MAR M H,et al.Choline availability during embryonic development alters progenitor cell mitosis in developing mouse hippocampus[J].J Nutr,2003,133(11):3614-3618.
[15]TRAIFFORT E,RUAT M,O’REGAN S,et al.Molecular characterization of the family of choline transporter-like proteins and their splice variants[J].J Neurochem,2005,92(5):1116-1125.
[16]王思,曲玥阳,肖桂山.SLC44A5对肺腺癌细胞迁移影响[J].大连理工大学学报,2022,62(6):570-575.
[17]PENG G Z,YE Q F,WANG R,et al.Knockdown by shRNA identifies SLC44A5 as a potential therapeutic target in hepatocellular carcinoma[J].Mol Med Rep,2016,13(6):4845-4852.
[18]CIOCIRLAN M,LAPALUS M G,HERVIEU V,et al.Endoscopic mucosal resection for squamous premalignant and early malignant lesions of the esophagus[J].Endoscopy,2007,39(1):24-29.
[19]NAGASHIMA F,NISHIYAMA R,IWAO B,et al.Molecular and functional characterization of choline transporter-like proteins in esophageal cancer cells and potential therapeutic targets[J].Biomol Ther (Seoul),2018,26(4):399-408.
[20]HASHIMOTO N,NAKAJIMA K,AKASHI Y,et al.Choline transporter-like protein 1 in tongue squamous cell carcinoma:Implications for cell proliferation and differentiation[J].Sci Rep,2025,15(1):31927.
[21]LIU Y P,MA L,WANG S J,et al.Prognostic value of lymph node metastases and lymph node ratio in esophageal squamous cell carcinoma[J].Eur J Surg Oncol,2010,36(2):155-159.
[22]D’JOURNO X B.Clinical implication of the innovations of the 8th edition of the TNM classification for esophageal and esophago-gastric cancer[J].J Thorac Dis,2018,10(Suppl 22):S2671-S2681.
[23]HU J F,SONG X,ZHONG K,et al.Increases prognostic value of clinical-pathological nomogram in patients with esophageal squamous cell carcinoma[J].Front Oncol,2023,13:997776.
[24]LI P,CHENG X,WU Y,et al.A new combined prognostic model involving SLC44A4 improves the predictive ability for colorectal cancer patients[J].Transl Cancer Res,2025,14(11):7725-7740.
[25]SHIBATA K,NISHIJIMA N,HIRAI K,et al.A novel plant-derived choline transporter-like protein 1 inhibitor,Amb544925,induces apoptotic cell death via the ceramide/survivin pathway in tongue squamous cell carcinoma[J].Cancers (Basel),2022,14(2):329.
[26]ZHAO J,CHEN B,DENG Y,et al.ChREBP-mediated choline deprivation and chemokine secretion shape tumor-associated macrophages to promote immune evasion[J].Cancer Res,2025,85(23):4701-4717.
[27]YANG Y,ZHENG L,HE J,et al.SLC44A2 negatively regulates mitochondrial fatty acid oxidation to suppress colorectal progression by blocking the MUL1-CPT2 interaction[J].Cell Death Dis,2025,16(1):468.

相似文献/References:

[1]林晓溪,张俊毅.斑菲素蛋白2在食管鳞状细胞癌组织中的表达及临床意义[J].陕西医学杂志,2022,51(6):741.[doi:DOI:10.3969/j.issn.1000-7377.2022.06.024]
　LIN Xiaoxi,ZHANG Junyi.Expression of plakophilin 2 in esophageal squamous cell carcinoma and its clinical significance[J].,2022,51(8):741.[doi:DOI:10.3969/j.issn.1000-7377.2022.06.024]
[2]李 玲,白春英,张俊毅,等.5-脂氧合酶激活蛋白在食管鳞状细胞癌组织中的表达及临床意义[J].陕西医学杂志,2022,51(6):745.[doi:DOI:10.3969/j.issn.1000-7377.2022.06.025]
　LI Ling,BAI Chunying,ZHANG Junyi,et al.Expression of five lipoxygenase activating protein in esophageal squamous cell carcinoma and its clinical significance[J].,2022,51(8):745.[doi:DOI:10.3969/j.issn.1000-7377.2022.06.025]
[3]刘光林,蒋佳伶,黄丹,等.HDAC7调控恶性肿瘤作用及机制研究进展[J].陕西医学杂志,2025,54(6):852.[doi:DOI:10.3969/j.issn.1000-7377.2025.06.025]
　LIU Guanglin,JIANG Jialing,HUANG Dan,et al.Research progress on role and mechanism of histone deacetylase 7 in regulating malignant tumors[J].,2025,54(8):852.[doi:DOI:10.3969/j.issn.1000-7377.2025.06.025]

备注/Memo

备注/Memo:
国家自然科学基金资助项目（82160542）；江苏省科技项目（BK20251717）；南京鼓楼医院临床研究专项资金项目（2023-LCYJ-MS-17）
更新日期/Last Update: 2026-08-13